Title |
Advances in small molecule inhibitors of androgen receptor for the treatment of advanced prostate cancer
|
---|---|
Published in |
World Journal of Urology, August 2011
|
DOI | 10.1007/s00345-011-0745-5 |
Pubmed ID | |
Authors |
Marianne D. Sadar |
Abstract |
Current treatments for localized prostate cancer include brachytherapy, external beam radiation, surgery, and active surveillance. Unfortunately, 20-40% of prostate cancer patients will experience recurrence and require hormonal therapies. These therapies involve androgen ablation by chemical or surgical castration and application of antiandrogens. Hormonal therapy is initially effective, but will inevitably fail and the disease will progress to lethal castration-resistant prostate cancer (CRPC) from which patients succumb within 2 years. CRPC is considered to be dependent on transcriptionally active androgen receptors (AR). This article reviews recent advances in the discovery and development of small molecule inhibitors of AR. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Canada | 1 | 3% |
Unknown | 39 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 9 | 23% |
Student > Bachelor | 7 | 18% |
Other | 5 | 13% |
Researcher | 5 | 13% |
Professor > Associate Professor | 3 | 8% |
Other | 7 | 18% |
Unknown | 4 | 10% |
Readers by discipline | Count | As % |
---|---|---|
Chemistry | 10 | 25% |
Medicine and Dentistry | 8 | 20% |
Agricultural and Biological Sciences | 6 | 15% |
Biochemistry, Genetics and Molecular Biology | 4 | 10% |
Computer Science | 1 | 3% |
Other | 5 | 13% |
Unknown | 6 | 15% |